HCA Healthcare Analysts Slash Their Forecasts After Q2 Results

Benzinga Earnings

07/27

HCA Healthcare Inc. (NYSE:HCA) on Friday posted upbeat second-quarter earnings.

The company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.

HCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70. The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.

HCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

Barclays analyst Andrew Mok maintained the stock with an Equal-Weight rating and lowered the price target from $402 to $387.
Baird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $396 to $393.
Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $475 to $435.
Oppenheimer analyst Michael Wiederhorn maintained HCA Healthcare with an Outperform rating and lowered the price target from $520 to $485.
Truist Securities analyst David Macdonald maintained the stock with a Buy and lowered the price target from $535 to $495.

Considering buying HCA stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2654049222"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654049222\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654049222?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654049222","market":"us","top_or_hot":-1,"title":"HCA Healthcare Analysts Slash Their Forecasts After Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong>HCA Healthcare Inc.</strong> (NYSE:HCA) on Friday posted upbeat second-quarter earnings.</p>\n<p>The company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.</p>\n<p>HCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70. The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.</p>\n<p>HCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.</p>\n<p>These analysts made changes to their price targets on HCA Healthcare following earnings announcement.</p>\n<ul>\n<li>Barclays analyst Andrew Mok maintained the stock with an Equal-Weight rating and lowered the price target from $402 to $387.</li>\n<li>Baird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $396 to $393.</li>\n<li>Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $475 to $435.</li>\n<li>Oppenheimer analyst Michael Wiederhorn maintained HCA Healthcare with an Outperform rating and lowered the price target from $520 to $485.</li>\n<li>Truist Securities analyst David Macdonald maintained the stock with a Buy and lowered the price target from $535 to $495.</li>\n</ul>\n<p><strong>Considering buying HCA stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"406\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-1024x406.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-1024x406.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-300x119.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-768x304.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770.png 1211w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HCA Healthcare Analysts Slash Their Forecasts After Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHCA Healthcare Analysts Slash Their Forecasts After Q2 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2026-07-27 23:41</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>HCA Healthcare Inc.</strong> (NYSE:HCA) on Friday posted upbeat second-quarter earnings.</p>\n<p>The company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.</p>\n<p>HCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70. The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.</p>\n<p>HCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.</p>\n<p>These analysts made changes to their price targets on HCA Healthcare following earnings announcement.</p>\n<ul>\n<li>Barclays analyst Andrew Mok maintained the stock with an Equal-Weight rating and lowered the price target from $402 to $387.</li>\n<li>Baird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $396 to $393.</li>\n<li>Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $475 to $435.</li>\n<li>Oppenheimer analyst Michael Wiederhorn maintained HCA Healthcare with an Outperform rating and lowered the price target from $520 to $485.</li>\n<li>Truist Securities analyst David Macdonald maintained the stock with a Buy and lowered the price target from $535 to $495.</li>\n</ul>\n<p><strong>Considering buying HCA stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"406\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-1024x406.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-1024x406.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-300x119.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770-768x304.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/27114002/image-770.png 1211w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2244417387.USD","symbol_name":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60701052/hca-healthcare-analysts-slash-their-forecasts-after-q2-results","article_id":"2654049222","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654049222","pubTimestamp":1785166899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"HCA Healthcare&#39;s Q2 earnings beat expectations with $20.23B in revenue and adjusted earnings of $7.59 per share. Analysts lower price targets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4185":"保健护理机构","XLV":"健康照护类股ETF-SPDR","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","JOYT":"JPMorgan Equity and Options Total Return ETF","LABU":"三倍做多标普生物-Direxion","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4581":"高盛持仓","RGLO":"Global Equity Active ETF","GXDW":"Global X Dorsey Wright Thematic ETF","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","XBI":"SPDR S&P Biotech ETF","HCA":"HCA控股","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","VOTE":"TCW Transform 500 ETF","LU0882574055.USD":"富达全球健康医疗A ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","PMDE":"PGIM S&P 500 Max Buffer ETF - December","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IHF":"iShares Dow Jones U.S. Health Ca","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4504":"桥水持仓","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","VGFPF":"Vanguard Funds PLC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H"},"translate_title":"HCA 医疗保健分析师在第二季度业绩公布后下调了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GXDW":0.61,"PMDE":0.61,"IHF":0.6,"VGFPF":0.61,"RGLO":0.61,"XLV":1.5,"JOYT":0.61,"XBI":0.6,"FEBU":0.61,"HCA":1.5,"VOTE":0.61,"DECU":0.61,"LABU":0.6},"content_text":"HCA Healthcare Inc. (NYSE:HCA) on Friday posted upbeat second-quarter earnings.\nThe company posted second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a year ago, surpassing the Wall Street estimates of $7.02.\nHCA Healthcare reaffirmed fiscal 2026 earnings guidance of $28.70-$30.50 per share compared to the consensus of $29.70. The company expects 2026 sales of $77 billion-$79.50 billion versus the consensus of $78.457 billion.\nHCA Healthcare shares gained 2.34% to trade at $391.35 on Monday.\nThese analysts made changes to their price targets on HCA Healthcare following earnings announcement.\n\nBarclays analyst Andrew Mok maintained the stock with an Equal-Weight rating and lowered the price target from $402 to $387.\nBaird analyst Michael Ha maintained the stock with a Neutral and lowered the price target from $396 to $393.\nKeybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and lowered the price target from $475 to $435.\nOppenheimer analyst Michael Wiederhorn maintained HCA Healthcare with an Outperform rating and lowered the price target from $520 to $485.\nTruist Securities analyst David Macdonald maintained the stock with a Buy and lowered the price target from $535 to $495.\n\nConsidering buying HCA stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}